Saravut Weroha is an Oncology physician affiliated with Mayo Clinic. OpenAlex indexes 56 publications with 726 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20251 payment
- Eli Lilly and CompanyProgram year20252 payments
- ABBVIE INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
66.2%PD-1 inhibitor34%Pembrolizumab100%Part B, office-administered≥17 patientsCD38-directed Cytolytic Antibody30.6%Daratumumab100%Part B, office-administered≥14 patients+ 2 more classes in this area
Metabolism & gastrointestinal
30.7%Other antiemetics25.5%Fosaprepitant100%Part B, office-administered≥17 patientsSerotonin-3 Receptor Antagonist5.3%Palonosetron hcl52%Ondansetron hydrochloride44%Ondansetron Hcl4%Part D + Part B≥28 patientsSensory organs
2.5%Corticosteroid2.5%Dexamethasone sodium phosphate85%Dexamethasone15%Part D + Part B≥22 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
- Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic
Mayo Clinic Rochester
FY2025$771,113K12CA090628
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Bradley Boeve, MD
Mayo Clinic
S Rajkumar, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic
Ayalew Tefferi, MD
Mayo Clinic
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”